

Intersect ENT Named One of *Forbes* Magazine's "America's Most Promising Companies" of 2014

Menlo Park, Calif. – Jan. 23, 2014 – Intersect ENT, Inc., an innovator in treatment solutions for ear, nose and throat clinicians and their patients, today announced that the company has been named by *Forbes* Magazine as one of "America's Most Promising Companies" of 2014. The annual ranking includes privately-held high-growth companies with annual revenue under \$250 million, taking into account growth, quality of management team and investors, margins, market size and key partnerships.

"Producing a ranking in the opaque world of privately-held companies is never easy. But we're confident that many of these are the IPOs and billion-dollar acquisitions of tomorrow," writes J.J. Colao in an article accompanying the list.

"We are honored to receive this prestigious recognition from *Forbes*," said Lisa Earnhardt, president and CEO of Intersect ENT. "We are proud of the way we've built and grown our business, and we look forward to continuing that growth by expanding our reach in the U.S. significantly this year and by developing additional products that bring value to patients, physicians and the health care system alike."

Intersect ENT's PROPEL[®] and PROPEL[®] mini implants are the first and only drug-eluting stents for patients with chronic sinusitis. The products release mometasone furoate, an advanced steroid with anti-inflammatory properties, directly into the sinus lining, then dissolve. Use of PROPEL maintains the open passages created in surgery leading to reduced need for oral medication and additional surgical procedures. The company is also studying a novel in-office solution for patients suffering from chronic sinusitis in a randomized clinical trial called the RESOLVE Study.

Chronic sinusitis is a condition in which patients' sinuses become swollen and inflamed, leading to difficulty breathing, facial pain or headache, and reduced sense of smell and taste. The condition is common, affecting 31 million people in the U.S., and greatly impacts quality of life. Chronic sinusitis often requires a complex combination of surgical and medical treatments. Each year, 500,000 patients undergo sinus surgery to treat the condition.

About Intersect ENT

Intersect ENT Inc., located in Menlo Park, Calif., is a growth-stage drug-device company focused on advancing clinically proven therapy solutions that improve quality of life for patients with ear, nose and throat conditions. The company's initial products, the PROPEL and PROPEL mini dissolvable steroid-releasing implants, are the only products backed by Level 1-A clinical evidence to improve sinus surgery outcomes for patients suffering from chronic sinusitis. The company holds twenty-three issued U.S. patents and more than 80 patents and pending applications worldwide. Intersect ENT is backed by Kleiner Perkins Caufield & Byers; U.S. Venture Partners; PTV Sciences; Norwest Venture Partners, and Medtronic. For more information please visit www.intersectENT.com.

###

Media Contact:

Nicole Osmer
650.454.0504
nicole@nicoleosmer.com